<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905591</url>
  </required_header>
  <id_info>
    <org_study_id>201712770</org_study_id>
    <secondary_id>3P30CA086862</secondary_id>
    <secondary_id>5U01CA140206</secondary_id>
    <nct_id>NCT02905591</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC</brief_title>
  <acronym>XACT-LUNG</acronym>
  <official_title>A Phase 2 Trial of Pharmacological Ascorbate With Concurrent Chemotherapy and Radiation Therapy Followed by Consolidation Chemotherapy for Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bryan Allen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy
      for non-small cell lung cancer. The standard therapy is radiation therapy combined with
      carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose
      ascorbate in addition to the standard therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For selected stages of non-small cell lung cancer (NSCLC), standard treatment involves
      radiation therapy and chemotherapy. The chemotherapy regimen typically used is paclitaxel and
      carboplatin. Both of these chemotherapeutic drugs are administered intravenously, using a
      vein in the arm. Radiation is administered using a machine external to the body (usually a
      linear accelerator). After combined therapy, NSCLC patients receive 2 extra cycles of
      chemotherapy, called &quot;consolidation chemotherapy.&quot;

      This study adds 75 grams of ascorbate (vitamin C, sometimes called pharmacological ascorbate
      because the dose is so high) at specific timepoints in the therapy. The ascorbate is
      administered intravenously - through a vein in your arm.

      Participants will:

        -  receive 75 grams of intravenous ascorbate 3 times per calendar week while they are
           receiving radiation therapy. The IV will be running while the radiation therapy is
           administered. This portion of the study is about 6 to 7 weeks.

        -  receive 75 grams of intravenous ascorbate 2 times per calendar week while they are
           receiving consolidation chemotherapy. Each cycle of consolidation chemotherapy is 3
           weeks, so this portion of the study is about 6 weeks.

        -  undergo imaging which is standard for their cancer and therapy. This can include CT
           scans, PET scans, and X-rays.

        -  provide blood samples to determine the biological effects, if any, the ascorbate has on
           the body during therapy

      This active therapy portion lasts for about 15 to 17 weeks. After that is done, participants
      go back to standard follow-up for their cancer and any additional therapy their doctors
      believe they need.

      However, it is very important the investigators remain in contact with participants; they
      will have life-long follow-up for this study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Every three months for up to 20 years post-treatment</time_frame>
    <description>Time, measured in months, from start of radiation to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Every six months for up to 20 years post-treatment</time_frame>
    <description>Time, measured in days, it takes for disease to progress, where disease progression is defined by the RECIST criteria (v1.1). Timeframe is from radiation day 1 to date of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Every six months for up to 20 years post-treatment</time_frame>
    <description>From radiation day 1 to documented disease progression as described by RECIST criteria. Results are provided in nominal categories (CR, PR, SD, PD) as per RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event frequency and categorization</measure>
    <time_frame>Weekly for the first 7 weeks, then monthly for 3 months, then every 6 months through 2 years post-treatment</time_frame>
    <description>Categorize and quantify adverse events using the Common Terminology Criteria for Adverse Events (CTCAE, v 4) as follows:
Through radiation, weekly assessment of adverse events
Consolidation chemotherapy, assessment day 1 of each cycle
Post-treatment, every 6 months through 2 years post-therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Concurrent and consolidation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent therapy:
Radiation therapy, intravenous paclitaxel, intravenous carboplatin, intravenous ascorbic acid (pharmacological ascorbate)
Consolidation therapy:
Intravenous paclitaxel, intravenous carboplatin, intravenous ascorbate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days</description>
    <arm_group_label>Concurrent and consolidation therapy</arm_group_label>
    <other_name>external beam radiation therapy (EBRT)</other_name>
    <other_name>intensity modulated radiation therapy (IMRT)</other_name>
    <other_name>Volumetric Arc Therapy (VMAT)</other_name>
    <other_name>XRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered
During concurrent phase:
the dose is 45 mg/m2 (standard dose)
Administered weekly
6 to 7 weeks of therapy, depending on when radiation starts
Standardized dose reductions are used
Consolidation phase:
Begins 3 to 4 weeks after completing radiation therapy
Prescribed at 200 mg/m3 (standard dose)
Given once every 21 days (i.e., one cycle)
Up to 2 cycles are administered
Standard dose reductions are used</description>
    <arm_group_label>Concurrent and consolidation therapy</arm_group_label>
    <other_name>Nov-Onxol</other_name>
    <other_name>Onxol</other_name>
    <other_name>Paclitaxel Novaplus</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.
During concurrent phase:
Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)
Administered weekly
6 to 7 weeks of therapy, depending on when radiation starts
Standard dose reductions are used
Consolidation phase:
Begins 3 to 4 weeks after radiation
Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)
Given once every 21 days (i.e., once cycle)
Two cycles are administered
Standard dose reductions are used</description>
    <arm_group_label>Concurrent and consolidation therapy</arm_group_label>
    <other_name>NovaPlus CARBOplatin</other_name>
    <other_name>Amerinet Choice Carboplatin</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin NovaPlus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Administered intravenously
Concurrent phase:
75 grams per infusion; each infusion is about 2 hours
3 infusion per calendar week
The infusion is actively running for at least 20 minutes when radiation begins
May be given while chemotherapy is delayed due to low counts
Dose reductions are not used
Given for 6 to 7 weeks, depending on when radiation starts
Consolidation phase:
75 grams per infusion, taking about 2 hours
2 infusions per calendar week; the days are normally back-to-back
May be given while chemotherapy is delayed due to low counts
Administered after paclitaxel and carboplatin
Two cycles are administered
Dose reductions are not used</description>
    <arm_group_label>Concurrent and consolidation therapy</arm_group_label>
    <other_name>Ascorbate</other_name>
    <other_name>Vitamin C</other_name>
    <other_name>Pharmacological ascorbate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Note: patients who have a small pleural effusion that is too small to safety tap and is not
        visible on a chest x-ray are still eligible

          -  Pathologic diagnosis (i.e., cell sample, biopsy, tissue swap, bronchoscopy) with
             non-small cell lung cancer.

          -  Diagnosed within the past 4 weeks

          -  Physician determined the patient is healthy enough for chemotherapy and radiation
             therapy

          -  At least part of the lung cancer must be viewable and measurable by CT or MRI

          -  A platelet count of at least 100,000 cells per mL

          -  A creatinine level of less than 1 1/2 times the upper limit of normal for the local
             lab test, or, a creatinine clearance of at least 60 mL/(min*1.73m2)

          -  Not pregnant, and commit to using birth control during the study

        Exclusion Criteria:

          -  Exudative pleural effusion

          -  Recurrent non-small cell lung cancer

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Patients actively receiving insulin

          -  Patients requiring daily finger-stick blood glucose measurements

          -  Patients who are on the following drugs and cannot have a substitution or who decline
             the substitution:

               -  warfarin

               -  flecainide

               -  methadone

               -  amphetamines

               -  quinidine

               -  chlorpropamide

          -  Prior radiation therapy that would result in a field overlap

          -  Enrolled in another therapeutic clinical trial

          -  Uncontrolled, intercurrent illness

          -  Lactating women

          -  HIV positive individuals undergoing therapy due to known drug:drug interaction between
             antiretroviral drugs and high-dose ascorbate therapy

        If all the above are met, the potential participant will receive a 15 gram challenge dose
        of ascorbate via intravenous infusion. This is the final screening procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph J Cullen, MD, FACS</last_name>
    <role>Study Director</role>
    <affiliation>The University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryan G Allen, MD, PhD</last_name>
    <phone>319-353-8836</phone>
    <email>bryan-allen@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muhammad Furqan, MD</last_name>
    <phone>319-356-1527</phone>
    <email>muhammad-furqan@uiowa.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O(2)(â‹…-) and H(2)O(2)-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268.</citation>
    <PMID>28366679</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Bryan Allen</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>pharmacological ascorbate</keyword>
  <keyword>ascorbic acid</keyword>
  <keyword>radiation</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared using clinicaltrials.gov reports and per the NIH data sharing plan on file with the grants.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

